- Conditions
- Corona Virus Infection, Flu Vaccine, Immunity
- Interventions
- Flu shot
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 9 Years to 64 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 326
matching trials from the live ClinicalTrials.gov search.
- Conditions
- SARS-CoV-2
- Interventions
- Not listed
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124,879 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sickle Cell Disease, COVID-19 Vaccine, Vaccine Hesitancy
- Interventions
- SCD-specific COVID-19 vaccination information (SCVI) video
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
- Conditions
- Covid19, SARS-CoV2 Infection
- Interventions
- mRNA-1273
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Myocarditis
- Interventions
- Cardiac Imaging
- Diagnostic Test
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Madera, California • Hartford, Connecticut + 14 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1283, mRNA-1273
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 13
- States / cities
- Ontario, California • Miami, Florida • Miami Lakes, Florida + 9 more
- Conditions
- COVID - 19
- Interventions
- FDA approved mRNA vaccines
- Biological
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 3 Years and older
- Enrollment
- 2,519 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 20
- States / cities
- Kissimmee, Florida • Chicago, Illinois • Oak Park, Illinois + 15 more
- Conditions
- COVID-19, Vaccination, Healthy Volunteer
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2050
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273 Variant-containing Formulation
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 1,144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Baton Rouge, Louisiana + 3 more
- Conditions
- Vaccination Refusal, COVID-19
- Interventions
- Short Message Service (SMS) + Website Link Strategy, Phone Call with Peer Strategy
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 262 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Hazelwood, Missouri • Jennings, Missouri • Saint Ann, Missouri + 2 more
- Conditions
- Covid19, Cancer
- Interventions
- Blood Sample
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- SARS-CoV Infection, Covid19
- Interventions
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 33,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
- Conditions
- COVID-19, Sars-CoV-2 Infection
- Interventions
- NVX-CoV2705, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 6,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 99
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
- Conditions
- Covid19
- Interventions
- SMS delivery of information, Personalized text message delivery of information, Interactive or 2-way SMS delivery of information
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,722 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Influenza,Human, COVID-19
- Interventions
- Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Placebo
- Biological · Combination Product · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,353 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 22
- States / cities
- Lake Forest, California • San Diego, California • Walnut Creek, California + 17 more
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Interventions
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- Interventions
- NVX-CoV2705 Vaccine
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Austin, Texas
- Conditions
- Healthy Participants
- Interventions
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 37
- States / cities
- Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
- Conditions
- SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
- Interventions
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 4,338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
- Conditions
- Immunization
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Iowa State University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Ames, Iowa
- Conditions
- SARS-CoV, SARS-CoV-2
- Interventions
- VXCO-100
- Biological
- Lead sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Baltimore, Maryland • Rochester, New York
- Conditions
- Health Behavior, Health Care Utilization, Vaccine Hesitancy
- Interventions
- Self-Affirmation Implementation Intentions (SAII) Intervention, Promotores de Salud (Health Education)
- Behavioral
- Lead sponsor
- University of Oregon
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- SARS-CoV-2 Infection, COVID-19, Maternal Immunization
- Interventions
- BNT162b2, Placebo
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 726 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 28 more